Milestone Pharmaceuticals, Inc.’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment for paroxysmal supraventricular tachycardia (PSVT). Now, the company plans to initiate a Phase III trial in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) after the drug was similarly effective at lowering heart rate in the Phase II ReVeRA study of AFib-RVR patients.
Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success
Approval For PSVT Pending At The US FDA
The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.
